Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS)

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

April 24, 2017

Primary Completion Date

December 23, 2020

Study Completion Date

December 23, 2020

Conditions
ALS
Interventions
DRUG

Perampanel

4mg/d or 8mg/d

DRUG

placebo

placebo

Trial Locations (12)

Unknown

Kitasato University East Hospital, Kanagawa

Kumamoto Saishunso National Hospital, Kumamoto

Nagoya University Hospital, Nagoya

Okayama University Hospital, Okayama

Hokkaido University Hospital, Sapporo

Tohoku University Hospital, Sendai

Shiga University of Medical Science Hospital, Shiga

The University of Tokyo Hospital, Tokyo

Tokyo Metropolitan Neurological Hospital, Tokyo

University of Tsukuba Hospital, Tsukuba

Yamaguchi University Hospital, Yamaguchi

160-0023

Tokyo Medical University, Tokyo

All Listed Sponsors
lead

Tokyo Medical University

OTHER

NCT03019419 - Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter | Biotech Hunter